出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年4月
Apheresis Market – Global Forecast to 2029
アフェレシス市場 : 製品別のサイズ [デバイス (遠心分離、膜分離) 、使い捨て]、手順 (ドナー、治療)、用途 (血漿交換、血小板交換)、テクノロジー、エンドユーザー (病院、採血センター)、地域別 – 2029年までの世界予測
Apheresis Market Size by Product (Device (Centrifugation, Membrane Separation) Disposable), Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region – Global Forecast to 2029
| ページ数 | 330 |
| 図表数 | 451 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレートライセンス | USD 8,150 |
| エンタープライズサイトライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
Report Overview
The global apheresis market is projected to reach USD 3.9 billion by 2029 from USD 2.6 billion in 2024, at a CAGR of 8.8% from 2024 to 2029.
世界のアフェレシス市場は、2024年から2029年までCAGR 8.8%で、2024年の26億米ドルから2029年までに39億米ドルに達すると予測されています。
The growth of the market is driven by a rising incidence of trauma and injury cases, upsurging number of complex surgical procedure. The market also benefits from rise in investments from government bodies and key players and the surge in use of apheresis procedure for leukaemia and paediatric patients.
However, significant expenses associated with apheresis devices and therapeutic procedures, along with the option of installing apheresis devices via rental agreements, are impacting the industry. Moreover, decline in apheresis-based blood donations due to insufficient awareness among potential donors is a major factor restraining the market growth.
“Therapeutic apheresis disposables segment to witness the highest growth during the forecast period.”
Based on procedure, the segment is divided into automated blood collection and therapeutic apheresis. The therapeutic apheresis is further divided into therapeutic apheresis disposables and therapeutic apheresis devices. The therapeutic apheresis disposables witness the highest growth in the apheresis market during the forecast period, attributing to rise in awareness about apheresis procedures, particularly for therapeutic purposes. This increased awareness has led to a growing acceptance of apheresis as an effective treatment option among healthcare providers and patients alike. Moreover, there is a significant increase in research activities focusing on apheresis procedures for therapeutic applications. This ongoing research is uncovering new insights into the efficacy and versatility of apheresis in treating various medical conditions, ranging from autoimmune disorders to hematologic malignancies. Thus, healthcare professionals are increasingly incorporating these procedures into their treatment protocols. As a result, the demand for therapeutic apheresis procedures is expected to surge in the coming years.
“Continuous flow centrifugation segment accounted for the largest share in the apheresis market during the forecast period.”
Based on technology, the apheresis market is segmented into centrifugation, and membrane separation. The centrifugation segment is further divided into continuous flow centrifugation and intermittent flow centrifugation. Among these, the continuous flow centrifugation segment accounted for largest share in the apheresis market in 2023. As continuous flow centrifugation technology is highly preferred in both blood collection and therapeutic apheresis procedures due to its efficiency and effectiveness. This technology allows for a smoother and more consistent separation process, leading to higher yields of desired blood components. As a result, healthcare facilities and blood collection centers Favor continuous flow centrifugation systems to streamline their operations and improve overall productivity. Moreover, continuous flow centrifugation technology offers several distinct advantages, such as its ability to operate with a small extracorporeal volume (ECV), minimizing the patient’s exposure to extracorporeal circulation. Additionally, this technology is associated with shorter procedural times and requires relatively low volumes of anticoagulants, which enhances patient safety and comfort. These advantages make continuous flow centrifugation a preferred choice among healthcare providers, thus increasing the market growth during forecasting period.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the apheresis market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period, attributing to expansion of healthcare infrastructure and blood banking facilities. This is due to increasing support from governments across the region for the development of healthcare infrastructure. These countries are growing economically thus, governments are allocating substantial resources towards enhancing healthcare services, including the establishment of modern medical facilities and the adoption of advanced medical technologies like apheresis devices. Moreover, increasing awareness of the importance of safe blood transfusions and the need for advanced blood collection and processing techniques, governments and healthcare authorities are incentivizing the expansion and modernization of blood banking facilities. Thus, increasing the government-licensed and accredited blood banks, leading to rise in the growth of apheresis market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), Latin America and Middle East Africa (16%)
List of Companies Profiled in the Report
o Terumo BCT, Inc. (Japan)
o Fresenius SE & Co. KGaA (Germany)
o Haemonetics Corporation (US)
o Baxter International Inc. (US)
o Asahi Kasei Medical Co., Ltd. (Japan)
o B. Braun Melsungen AG (Germany)
o Cerus Corporation (US)
o Kaneka Corporation (Japan)
o SB-Kawasumi Laboratories, Inc (Japan)
o Nikkiso Co., Ltd (Japan)
o Macopharma SA (France)
o Miltenyi Biotec (Germany)
o Otsuka Holdings Co., Ltd. (Japan)
o Medica S.p.A. (Italy)
o Mallinckrodt plc (Ireland)
o Becton, Dickinson and Company (US)
o LMB Technologie GmbH (Germany)
o Bioelettronica S.r.l. (Italy)
o Infomed SA (Switzerland)
o Cytosorbents Corporation (US)
o Medicap clinic GmbH (Germany)
o Haier Biomedical (China)
o Beijing ZKSK Technology Co., Ltd. (China)
o Guangzhou Daji Medical Science and Technology Co. Ltd (China)
o PuriBlood Medical (Taiwan)
Research Coverage
This report studies the apheresis market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
• Analysis of key drivers (increasing prevalence of trauma and injury cases, rise in demand for source plasma from biopharmaceutical companies, upsurging number of complex surgical procedures, and favourable reimbursement for apheresis procedures) ,restraints (High cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through rental model, Fewer blood donations using apheresis due to lack of awareness, Stringent donor recruitment criteria), challenges (recruitment of voluntary non-remunerated donors, and safety of blood transfusion in developing countries), opportunities (apheresis for leukaemia and paediatric patients, and emerging economies with increasing investments from government authorities and key players) contributing the growth of the apheresis market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the apheresis market.
• Market Development: Comprehensive information on the lucrative emerging markets, product, procedure, technology, application, end-user and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the apheresis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global apheresis market.
Table of Contents
1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.2.1 PRODUCT DEFINITION 44
1.2.2 TECHNOLOGY DEFINITION 44
1.2.3 APPLICATION DEFINITION 44
1.2.4 END USER DEFINITION 45
1.2.5 INCLUSIONS & EXCLUSIONS 46
1.3 MARKET SCOPE 47
1.3.1 MARKETS COVERED 47
1.3.2 REGIONS COVERED 48
1.3.3 YEARS CONSIDERED 48
1.3.4 CURRENCY CONSIDERED 48
TABLE 1 CURRENCY CONVERSION RATES 49
1.4 STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 49
1.6 RECESSION IMPACT 50
2 RESEARCH METHODOLOGY 51
2.1 RESEARCH DATA 51
FIGURE 1 RESEARCH DESIGN 51
2.1.1 SECONDARY DATA 52
2.1.1.1 Key data from secondary sources 53
2.1.2 PRIMARY DATA 54
FIGURE 2 PRIMARY SOURCES 54
2.1.2.1 Key data from primary sources 55
2.1.2.2 Key industry insights 56
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 56
2.2 MARKET SIZE ESTIMATION 57
FIGURE 4 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 57
FIGURE 5 TOP-DOWN APPROACH 58
FIGURE 6 MARKET SIZE ESTIMATION: DEMAND-SIDE ASSESSMENT 59
FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029): IMPACT LEVEL 60
FIGURE 8 CAGR PROJECTIONS 60
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 62
FIGURE 9 DATA TRIANGULATION METHODOLOGY 62
2.4 MARKET RANKING ANALYSIS 63
2.5 STUDY ASSUMPTIONS 63
2.6 RISK ASSESSMENT 63
2.7 LIMITATIONS 63
2.7.1 METHODOLOGY-RELATED LIMITATIONS 63
2.8 RECESSION IMPACT ANALYSIS 64
3 EXECUTIVE SUMMARY 65
FIGURE 10 APHERESIS DISPOSABLES TO BE LARGEST SEGMENT DURING FORECAST PERIOD 65
FIGURE 11 CENTRIFUGAL APHERESIS DEVICES SEGMENT TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD 66
FIGURE 12 AUTOMATED BLOOD COLLECTION TO BE LEADING SEGMENT DURING FORECAST PERIOD 66
FIGURE 13 THERAPEUTIC APHERESIS DISPOSABLES TO HOLD DOMINANT SHARE BY 2029 67
FIGURE 14 NEUROLOGICAL DISORDERS TO BE LEADING SEGMENT DURING FORECAST PERIOD 67
FIGURE 15 CENTRIFUGATION TECHNOLOGY TO DOMINATE APHERESIS MARKET DURING FORECAST PERIOD 68
FIGURE 16 CONTINUOUS FLOW CENTRIFUGATION TO BE MAJOR SEGMENT DURING FORECAST PERIOD 69
FIGURE 17 PLASMAPHERESIS SEGMENT TO HOLD LARGEST SHARE BY 2029 69
FIGURE 18 COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS – MAJOR SEGMENT BY 2029 70
FIGURE 19 ASIA PACIFIC TO BE FASTEST-GROWING REGIONAL MARKET FOR APHERESIS 71
4 PREMIUM INSIGHTS 72
4.1 APHERESIS MARKET OVERVIEW 72
FIGURE 20 RISING PREVALENCE OF DISEASES AND GROWING NUMBER OF TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH 72
4.2 EUROPE: APHERESIS MARKET, BY APPLICATION & COUNTRY 73
FIGURE 21 PLASMAPHERESIS AND GERMANY ACCOUNTED FOR LARGEST SHARE OF EUROPEAN APHERESIS MARKET IN 2023 73
4.3 REGIONAL SNAPSHOT OF APHERESIS MARKET (2023) 74
FIGURE 22 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 74
4.4 REGIONAL MIX: APHERESIS MARKET, 2024–2029 (USD MILLION) 75
FIGURE 23 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 75
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION) 75
FIGURE 24 DEVELOPING MARKETS TO REGISTER FASTER GROWTH DURING FORECAST PERIOD 75
5 MARKET OVERVIEW 76
5.1 INTRODUCTION 76
5.2 MARKET DYNAMICS 76
FIGURE 25 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 76
5.2.1 DRIVERS 77
5.2.1.1 Rising prevalence of chronic diseases and trauma/injury cases 77
FIGURE 26 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION INDIVIDUALS) 78
5.2.1.2 Increasing demand for source plasma from biopharmaceutical companies 78
FIGURE 27 EUROPE: PLASMA COLLECTION, 2012–2021 (LITERS) 79
FIGURE 28 NORTH AMERICA: PLASMA COLLECTION, 2012–2021 (LITERS) 79
5.2.1.3 Rising demand for blood components and growing concerns regarding blood safety 79
5.2.1.4 Increase in complex surgical procedures 80
TABLE 2 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY 80
5.2.1.5 Favorable reimbursement policies for apheresis procedures 81
5.2.2 RESTRAINTS 81
5.2.2.1 High cost of procedures and installation through rental models 81
5.2.2.2 Limited use in blood donation due to low awareness 82
TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION 82
5.2.2.3 Stringent donor recruitment criteria 82
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 83
5.2.2.4 Dearth of skilled professionals and low adoption of therapeutic apheresis 83
5.2.3 OPPORTUNITIES 83
5.2.3.1 Apheresis for leukemia and pediatric patients 83
5.2.3.2 Emerging economies with increasing investments from government bodies and leading players 84
5.2.4 CHALLENGES 85
5.2.4.1 Recruitment of voluntary non-remunerated donors 85
5.2.4.2 Safety of blood transfusion in developing countries 85
5.3 INDUSTRY TRENDS 86
FIGURE 29 FOCUS ON PERSONALIZED MEDICINE, AUTOMATION, EFFICIENCY, AND EXPANSION OF APHERESIS APPLICATIONS – LEADING TRENDS 86
5.3.1 INCREASE IN FOCUS ON PERSONALIZED MEDICINE 86
5.3.2 INCREASE IN FOCUS ON AUTOMATION AND EFFICIENCY 87
5.3.3 EXPANSION OF APHERESIS APPLICATIONS 87
5.4 TECHNOLOGY ANALYSIS 88
5.4.1 KEY TECHNOLOGIES 88
5.4.1.1 Centrifugation 88
5.4.1.2 Membrane Filtration 88
5.4.1.3 Automated collection systems 89
5.4.2 COMPLEMENTARY TECHNOLOGY 89
5.4.2.1 Biocompatible Materials 89
5.4.2.2 Automation and robotics 90
5.4.2.3 Advanced imaging technologies 90
5.4.3 ADJACENT TECHNOLOGIES 91
5.4.3.1 Extracorporeal Photopheresis (ECP) 91
5.4.3.2 Continuous Renal Replacement Therapy (CRRT) 91
5.4.3.3 Hemodialysis 92
5.5 VALUE CHAIN ANALYSIS 92
FIGURE 30 APHERESIS MARKET: VALUE CHAIN ANALYSIS 93
5.6 PORTER’S FIVE FORCES ANALYSIS 93
TABLE 5 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 93
5.6.1 THREAT OF NEW ENTRANTS 93
5.6.2 THREAT OF SUBSTITUTES 94
5.6.3 BARGAINING POWER OF SUPPLIERS 94
5.6.4 BARGAINING POWER OF BUYERS 94
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 94
5.7 REGULATORY LANDSCAPE 95
5.7.1 REGULATORY ANALYSIS 95
5.7.1.1 North America 95
5.7.1.1.1 US 95
5.7.1.1.2 Canada 96
5.7.1.2 Europe 96
5.7.1.3 Asia Pacific 96
5.7.1.3.1 Japan 96
5.7.1.3.2 China 97
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
5.8 PATENT ANALYSIS 99
5.8.1 PATENT PUBLICATION TRENDS FOR APHERESIS MARKET 99
FIGURE 31 GLOBAL NUMBER OF PATENTS PUBLICATIONS (JANUARY 2014─MARCH 2024) 100
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 100
FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS (JANUARY 2014─ MARCH 2024) 101
FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR APHERESIS (JANUARY 2013─ MARCH 2024) 101
TABLE 11 LIST OF PATENTS IN APHERESIS MARKET, 2014–2024 102
5.9 HS CODES: APHERESIS INSTRUMENTS 103
TABLE 12 HS CODES FOR APHERESIS INSTRUMENTS 103
5.10 PRICING ANALYSIS 103
TABLE 13 PRICING OF APHERESIS PRODUCTS, 2023 (USD) 104
TABLE 14 PRICING ANALYSIS OF APHERESIS PRODUCTS (USD) 104
TABLE 15 REGIONAL PRICING ANALYSIS OF KEY APHERESIS PRODUCTS, 2023 (USD) 105
5.11 REIMBURSEMENT ANALYSIS 105
TABLE 16 REIMBURSEMENT ANALYSIS: FOR APHERESIS PROCEDURES 105
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 106
TABLE 17 APHERESIS MARKET: KEY CONFERENCES AND EVENTS, 2024–2025 106
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 107
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS 107
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS 107
5.13.2 BUYING CRITERIA 107
FIGURE 35 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS 107
TABLE 19 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS 108
5.14 UNMET NEEDS IN APHERESIS MARKET 108
TABLE 20 UNMET NEEDS: APHERESIS MARKET 108
5.15 END USER EXPECTATIONS IN APHERESIS MARKET 109
TABLE 21 END USER EXPECTATIONS: APHERESIS MARKET 109
5.16 AI INTEGRATION IN APHERESIS MARKET 109
TABLE 22 AI INTEGRATION: APHERESIS MARKET 109
5.17 ECOSYSTEM ANALYSIS 110
FIGURE 36 APHERESIS MARKET: ECOSYSTEM 111
TABLE 23 ECOSYSTEM OF APHERESIS MARKET 111
5.18 CASE STUDIES 112
5.18.1 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 112
5.18.2 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 112
5.18.3 CASE STUDY 3: THERAPEUTIC PLASMA EXCHANGE FOR MYASTHENIA GRAVIS 113
5.18.4 CASE STUDY 4: THERAPEUTIC APHERESIS FOR TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) 113
5.19 SUPPLY CHAIN ANALYSIS 114
FIGURE 37 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS 115
5.20 ADJACENT MARKET ANALYSIS 115
5.20.1 LEUKAPHERESIS MARKET 115
FIGURE 38 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW 116
FIGURE 39 LEUKOPAKS MARKET OVERVIEW 116
5.21 APHERESIS MARKET: INVESTMENT AND FUNDING SCENARIO 116
FIGURE 40 INVESTMENT AND FUNDING SCENARIO: APHERESIS MARKET (2018–2023) 117
6 APHERESIS MARKET, BY PRODUCT 118
6.1 INTRODUCTION 119
TABLE 24 APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 119
6.2 APHERESIS DISPOSABLES 119
6.2.1 RECURRENT USE OF APHERESIS DISPOSABLES TO BOOST GROWTH 119
TABLE 25 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 120
TABLE 26 KEY PLAYERS PROVIDING APHERESIS DISPOSABLES 120
6.3 APHERESIS DEVICES 121
TABLE 27 APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 122
TABLE 28 APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 122
6.3.1 CENTRIFUGAL APHERESIS DEVICES 123
6.3.1.1 Increasing installation in hospitals for therapeutic apheresis 123
TABLE 29 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 124
TABLE 30 KEY PLAYERS PROVIDING CENTRIFUGAL APHERESIS DEVICES 124
6.3.2 MEMBRANE SEPARATORS 125
6.3.2.1 Separation of huge volumes of plasma from milliliters of whole blood – key limiting factor 125
TABLE 31 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 126
TABLE 32 KEY PLAYERS PROVIDING MEMBRANE SEPARATORS 126
7 APHERESIS MARKET, BY PROCEDURE 127
7.1 INTRODUCTION 128
TABLE 33 APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 128
7.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS) 128
7.2.1 INCREASING NUMBER OF BLOOD COMPONENT DONATIONS USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH 128
TABLE 34 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS), BY COUNTRY, 2021–2029 (USD MILLION) 129
7.3 THERAPEUTIC APHERESIS 129
TABLE 35 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 130
TABLE 36 THERAPEUTIC APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 131
7.3.1 THERAPEUTIC APHERESIS DISPOSABLES 131
TABLE 37 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 132
TABLE 38 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 133
7.3.1.1 Neurological disorders 133
7.3.1.1.1 Hold major share in therapeutic apheresis disposables market 133
TABLE 39 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 134
7.3.1.2 Blood disorders 135
7.3.1.2.1 Increasing prevalence of hematologic and genetic disorders to boost demand 135
TABLE 40 BLOOD DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 135
7.3.1.3 Renal disorders 136
7.3.1.3.1 Regarded among most useful treatment options for several renal disorders 136
TABLE 41 RENAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 136
7.3.1.4 Autoimmune disorders 137
7.3.1.4.1 Vital support component for treatment of autoimmune disorders 137
TABLE 42 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 138
7.3.1.5 Metabolic disorders 138
7.3.1.5.1 Increasing adoption for treatment of diabetes and other metabolic disorders 138
TABLE 43 METABOLIC DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 139
7.3.1.6 Cardiovascular disorders 139
7.3.1.6.1 Low-density lipoprotein (LDL) apheresis mainly used in treatment of cardiovascular disorders 139
TABLE 44 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES, BY COUNTRY, 2021–2029 (USD MILLION) 140
7.3.1.7 Other disorders 140
TABLE 45 OTHER DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 141
7.3.2 THERAPEUTIC APHERESIS DEVICES 141
7.3.2.1 Centrifugation-based devices – most commonly adopted 141
TABLE 46 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 142
8 APHERESIS MARKET, BY TECHNOLOGY 143
8.1 INTRODUCTION 144
TABLE 47 APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 144
8.2 CENTRIFUGATION 144
TABLE 48 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION 144
TABLE 49 KEY PLAYERS PROVIDING CENTRIFUGATION TECHNOLOGY 145
TABLE 50 CENTRIFUGATION: APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 145
TABLE 51 CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 146
8.2.1 CONTINUOUS FLOW CENTRIFUGATION 146
8.2.1.1 Preferred in blood collection and therapeutic apheresis procedures 146
TABLE 52 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 147
8.2.2 INTERMITTENT FLOW CENTRIFUGATION 147
8.2.2.1 Need for single venipuncture site – major driving factor 147
TABLE 53 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 148
8.3 MEMBRANE SEPARATION 148
8.3.1 HIGH EFFICACY ACCOUNTS FOR HIGH USAGE IN DEVELOPED COUNTRIES 148
TABLE 54 SIZE OF BLOOD COMPONENTS 149
TABLE 55 KEY PLAYERS PROVIDING MEMBRANE SEPARATION TECHNOLOGY 149
TABLE 56 MEMBRANE SEPARATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 150
9 APHERESIS MARKET, BY APPLICATION 151
9.1 INTRODUCTION 152
TABLE 57 APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 152
9.2 PLASMAPHERESIS 152
9.2.1 LARGEST APPLICATION SEGMENT IN APHERESIS MARKET 152
TABLE 58 PLASMAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 154
9.3 PLATELETPHERESIS 154
9.3.1 INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO DRIVE GROWTH 154
TABLE 59 PLATELETPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 155
9.4 ERYTHROCYTAPHERESIS 156
9.4.1 INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN SURGICAL PROCEDURES TO DRIVE GROWTH 156
TABLE 60 ERYTHROCYTAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 157
9.5 LEUKAPHERESIS 157
9.5.1 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE SEGMENT 157
TABLE 61 LEUKAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 158
9.6 PHOTOPHERESIS 158
9.6.1 INCREASING PREVALENCE OF BLOOD DISORDERS AND ORGAN TRANSPLANT REJECTION TO DRIVE SEGMENT 158
TABLE 62 PHOTOPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 159
9.7 OTHER APPLICATIONS 159
TABLE 63 OTHER APPLICATIONS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 160
10 APHERESIS MARKET, BY END USER 161
10.1 INTRODUCTION 162
TABLE 64 APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 162
10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS 162
10.2.1 INCREASING AWARENESS OF BENEFITS OF APHERESIS TO FUEL SEGMENT 162
TABLE 65 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 163
10.3 HOSPITALS & TRANSFUSION CENTERS 163
10.3.1 RISING NUMBER OF COMPLEX SURGICAL PROCEDURES AND TRANSFUSIONS TO BOOST MARKET 163
TABLE 66 HOSPITALS & TRANSFUSION CENTERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 164
10.4 OTHER END USERS 165
TABLE 67 OTHER END USERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 165
11 APHERESIS MARKET, BY REGION 166
11.1 INTRODUCTION 167
FIGURE 41 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT 167
TABLE 68 APHERESIS MARKET, BY REGION, 2021–2029 (USD MILLION) 168
11.2 NORTH AMERICA 168
11.2.1 NORTH AMERICA: RECESSION IMPACT 168
FIGURE 42 NORTH AMERICA: APHERESIS MARKET SNAPSHOT 169
TABLE 69 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 170
TABLE 70 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 170
TABLE 71 NORTH AMERICA: DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 170
TABLE 72 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 171
TABLE 73 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 171
TABLE 74 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 171
TABLE 75 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 172
TABLE 76 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 172
TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 172
TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 173
11.2.2 US 173
11.2.2.1 Dominates North American apheresis market 173
TABLE 79 US: KEY MACROINDICATORS 174
TABLE 80 US: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 174
TABLE 81 US: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 174
TABLE 82 US: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 175
TABLE 83 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 175
TABLE 84 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 175
TABLE 85 US: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 176
TABLE 86 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 176
TABLE 87 US: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 176
TABLE 88 US: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 177
11.2.3 CANADA 177
11.2.3.1 Rising demand for plasma protein products to drive market growth 177
TABLE 89 CANADA: KEY MACROINDICATORS 178
TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 178
TABLE 91 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 178
TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 179
TABLE 93 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 179
TABLE 94 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 179
TABLE 95 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 180
TABLE 96 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 180
TABLE 97 CANADA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 180
TABLE 98 CANADA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 181
11.3 EUROPE 181
11.3.1 EUROPE: RECESSION IMPACT 182
TABLE 99 EUROPE: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 182
TABLE 100 EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 182
TABLE 101 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 102 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 183
TABLE 103 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 183
TABLE 104 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 184
TABLE 105 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 184
TABLE 106 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 184
TABLE 107 EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 185
TABLE 108 EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 185
11.3.2 GERMANY 185
11.3.2.1 Fastest-growing market for apheresis systems in Europe 185
TABLE 109 GERMANY: KEY MACROINDICATORS 186
TABLE 110 GERMANY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 186
TABLE 111 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 186
TABLE 112 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 187
TABLE 113 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 187
TABLE 114 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 187
TABLE 115 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 188
TABLE 116 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 188
TABLE 117 GERMANY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 188
TABLE 118 GERMANY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 189
11.3.3 FRANCE 189
11.3.3.1 Increasing need for blood components to boost market 189
TABLE 119 FRANCE: KEY MACROINDICATORS 189
TABLE 120 FRANCE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 190
TABLE 121 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 190
TABLE 122 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 190
TABLE 123 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 191
TABLE 124 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 191
TABLE 125 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 191
TABLE 126 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 127 FRANCE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 192
TABLE 128 FRANCE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 192
11.3.4 ITALY 193
11.3.4.1 Therapeutic plasma exchange and LDL apheresis – widely adopted procedures 193
TABLE 129 ITALY: KEY MACROINDICATORS 193
TABLE 130 ITALY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 193
TABLE 131 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 194
TABLE 132 ITALY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 194
TABLE 133 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 194
TABLE 134 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 195
TABLE 135 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 195
TABLE 136 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 195
TABLE 137 ITALY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 196
TABLE 138 ITALY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 196
11.3.5 UK 196
11.3.5.1 Growing consumption of plasma-derived products to fuel market growth 196
TABLE 139 UK: KEY MACROINDICATORS 197
TABLE 140 UK: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 197
TABLE 141 UK: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 198
TABLE 142 UK: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 198
TABLE 143 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2021–2029 (USD MILLION) 198
TABLE 144 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 199
TABLE 145 UK: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 199
TABLE 146 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 199
TABLE 147 UK: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 200
TABLE 148 UK: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 200
11.3.6 SPAIN 200
11.3.6.1 Growing demand for treatment of chronic diseases in the elderly 200
TABLE 149 SPAIN: KEY MACROINDICATORS 201
TABLE 150 SPAIN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 201
TABLE 151 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 152 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 202
TABLE 153 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 202
TABLE 154 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 202
TABLE 155 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 203
TABLE 156 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 203
TABLE 157 SPAIN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 203
TABLE 158 SPAIN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 204
11.3.7 REST OF EUROPE 204
TABLE 159 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 205
TABLE 160 REST OF EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 205
TABLE 161 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 205
TABLE 162 REST OF EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 206
TABLE 163 REST OF EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 206
TABLE 164 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 206
TABLE 165 REST OF EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 207
TABLE 166 REST OF EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 207
TABLE 167 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 207
11.4 ASIA PACIFIC 208
11.4.1 ASIA PACIFIC: RECESSION IMPACT 208
FIGURE 43 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT 209
TABLE 168 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 210
TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 210
TABLE 170 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 171 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 211
TABLE 172 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 211
TABLE 173 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 211
TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 212
TABLE 175 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 212
TABLE 176 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 212
TABLE 177 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 213
11.4.2 CHINA 213
11.4.2.1 Dominant Asia Pacific apheresis market 213
TABLE 178 CHINA: KEY MACROINDICATORS 213
TABLE 179 CHINA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 214
TABLE 180 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 181 CHINA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 214
TABLE 182 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 215
TABLE 183 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 215
TABLE 184 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 215
TABLE 185 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 216
TABLE 186 CHINA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 216
TABLE 187 CHINA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 216
11.4.3 JAPAN 217
11.4.3.1 Advanced technology and universal healthcare insurance – key drivers 217
TABLE 188 JAPAN: KEY MACROINDICATORS 217
TABLE 189 JAPAN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 217
TABLE 190 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 191 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 218
TABLE 192 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 218
TABLE 193 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 219
TABLE 194 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 219
TABLE 195 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 219
TABLE 196 JAPAN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 220
TABLE 197 JAPAN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 220
11.4.4 INDIA 220
11.4.4.1 Increasing demand for blood components and growing applications of plasma derivatives – key drivers 220
TABLE 198 INDIA: KEY MACROINDICATORS 221
TABLE 199 INDIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 221
TABLE 200 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 221
TABLE 201 INDIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 222
TABLE 202 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 222
TABLE 203 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 222
TABLE 204 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 223
TABLE 205 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 223
TABLE 206 INDIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 223
TABLE 207 INDIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 224
11.4.5 AUSTRALIA 224
11.4.5.1 Growing awareness campaigns to drive market growth 224
TABLE 208 AUSTRALIA: KEY MACROINDICATORS 224
TABLE 209 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 225
TABLE 210 AUSTRALIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 225
TABLE 211 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 225
TABLE 212 AUSTRALIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 226
TABLE 213 AUSTRALIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 226
TABLE 214 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 226
TABLE 215 AUSTRALIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 227
TABLE 216 AUSTRALIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 227
TABLE 217 AUSTRALIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 227
11.4.6 SOUTH KOREA 228
11.4.6.1 Rise in prevalence of blood cancers to drive market growth 228
TABLE 218 SOUTH KOREA: KEY MACROINDICATORS 228
TABLE 219 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 228
TABLE 220 SOUTH KOREA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 229
TABLE 221 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 229
TABLE 222 SOUTH KOREA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 229
TABLE 223 SOUTH KOREA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 230
TABLE 224 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 230
TABLE 225 SOUTH KOREA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 226 SOUTH KOREA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 231
TABLE 227 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 231
11.4.7 REST OF ASIA PACIFIC 231
TABLE 228 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 232
TABLE 229 REST OF ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 232
TABLE 230 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 232
TABLE 231 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 233
TABLE 232 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 233
TABLE 233 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 233
TABLE 234 REST OF ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 235 REST OF ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 234
TABLE 236 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 234
11.5 LATIN AMERICA 235
11.5.1 LATIN AMERICA: RECESSION IMPACT 235
TABLE 237 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 235
TABLE 238 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 236
TABLE 239 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 236
TABLE 240 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 236
TABLE 241 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 237
TABLE 242 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 237
TABLE 243 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 237
TABLE 244 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 245 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 238
TABLE 246 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 238
11.5.2 BRAZIL 239
11.5.2.1 Accounts for largest share of Latin American market 239
TABLE 247 BRAZIL: KEY MACROINDICATORS 239
TABLE 248 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 240
TABLE 249 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 240
TABLE 250 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 240
TABLE 251 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 241
TABLE 252 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 241
TABLE 253 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 241
TABLE 254 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 255 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 242
TABLE 256 BRAZIL: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 242
11.5.3 MEXICO 243
11.5.3.1 Rapidly growing geriatric population – key factor driving market growth 243
TABLE 257 MEXICO: KEY MACROINDICATORS 243
TABLE 258 MEXICO: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 243
TABLE 259 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 244
TABLE 260 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 244
TABLE 261 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 244
TABLE 262 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 245
TABLE 263 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 245
TABLE 264 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 245
TABLE 265 MEXICO: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 246
TABLE 266 MEXICO: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 246
11.5.4 REST OF LATIN AMERICA 246
TABLE 267 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 247
TABLE 268 REST OF LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 247
TABLE 269 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 247
TABLE 270 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 248
TABLE 271 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 248
TABLE 272 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 248
TABLE 273 REST OF LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 249
TABLE 274 REST OF LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 249
TABLE 275 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 249
11.6 MIDDLE EAST & AFRICA 250
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 250
TABLE 276 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 251
TABLE 277 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 251
TABLE 278 MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 251
TABLE 279 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 252
TABLE 280 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 252
TABLE 281 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 252
TABLE 282 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 253
TABLE 283 MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 253
TABLE 284 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 253
TABLE 285 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 254
11.6.2 GCC COUNTRIES 254
11.6.2.1 Increase in prevalence of chronic diseases to drive market 254
TABLE 286 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 255
TABLE 287 GCC COUNTRIES: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 255
TABLE 288 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 255
TABLE 289 GCC COUNTRIES: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 256
TABLE 290 GCC COUNTRIES: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 256
TABLE 291 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 256
TABLE 292 GCC COUNTRIES: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 257
TABLE 293 GCC COUNTRIES: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 257
TABLE 294 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 257
11.6.3 REST OF MIDDLE EAST & AFRICA 258
TABLE 295 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 258
TABLE 296 REST OF MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION) 258
TABLE 297 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION) 259
TABLE 298 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 259
TABLE 299 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION) 259
TABLE 300 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 260
TABLE 301 REST OF MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION) 260
TABLE 302 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 260
TABLE 303 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION) 261
12 COMPETITIVE LANDSCAPE 262
12.1 OVERVIEW 262
12.2 KEY PLAYER STRATEGIES 262
FIGURE 44 OVERVIEW OF STRATEGIES DEPLOYED BY APHERESIS MARKET PLAYERS 263
12.3 REVENUE SHARE ANALYSIS 264
FIGURE 45 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2023) 264
12.4 MARKET SHARE ANALYSIS 265
12.4.1 APHERESIS MARKET SHARE ANALYSIS 265
FIGURE 46 APHERESIS MARKET SHARE ANALYSIS (2023) 265
TABLE 304 APHERESIS MARKET: DEGREE OF COMPETITION 265
12.4.2 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS 267
FIGURE 47 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS (2023) 267
TABLE 305 CENTRIFUGATION MARKET: DEGREE OF COMPETITION 267
12.4.3 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS 268
FIGURE 48 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS (2023) 268
TABLE 306 MEMBRANE SEPARATION MARKET: DEGREE OF COMPETITION 268
12.5 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023) 269
12.5.1 STARS 269
12.5.2 EMERGING LEADERS 269
12.5.3 PERVASIVE PLAYERS 269
12.5.4 PARTICIPANTS 269
FIGURE 49 APHERESIS MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS, 2023 270
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 271
12.5.5.1 Company footprint 271
FIGURE 50 APHERESIS MARKET: COMPANY FOOTPRINT 271
12.5.5.2 Region footprint 271
TABLE 307 APHERESIS MARKET: REGION FOOTPRINT 271
12.5.5.3 Product footprint 272
TABLE 308 APHERESIS MARKET: PRODUCT FOOTPRINT 272
12.5.5.4 Procedure footprint 273
TABLE 309 APHERESIS MARKET: PROCEDURE FOOTPRINT 273
12.5.5.5 Technology footprint 273
TABLE 310 APHERESIS MARKET: TECHNOLOGY FOOTPRINT 273
12.5.5.6 Application footprint 274
TABLE 311 APHERESIS MARKET: APPLICATION FOOTPRINT 274
12.5.5.7 End user footprint 275
TABLE 312 APHERESIS MARKET: END USER FOOTPRINT 275
12.6 COMPANY EVALUATION MATRIX, START-UP/SMES (2023) 275
12.6.1 PROGRESSIVE COMPANIES 276
12.6.2 DYNAMIC COMPANIES 276
12.6.3 RESPONSIVE COMPANIES 276
12.6.4 STARTING BLOCKS 276
FIGURE 51 APHERESIS MARKET: COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023 277
12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023 277
TABLE 313 APHERESIS MARKET: KEY START-UPS/SMES 277
12.7 COMPETITIVE SCENARIO AND TRENDS 278
12.7.1 PRODUCT LAUNCHES & APPROVALS 278
TABLE 314 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–FEBRUARY 2024 278
12.7.2 DEALS 279
TABLE 315 APHERESIS MARKET: DEALS, JANUARY 2020–FEBRUARY 2024 279
12.7.3 OTHERS 280
TABLE 316 APHERESIS MARKET: OTHERS, JANUARY 2020–FEBRUARY 2024 280
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 281
TABLE 317 APHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 281
13 COMPANY PROFILES 283
13.1 KEY PLAYERS 283
(Business overview, Products/Solutions/Services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*
13.1.1 TERUMO BCT, INC. 283
TABLE 318 TERUMO BCT, INC.: BUSINESS OVERVIEW 283
FIGURE 52 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022) 284
TABLE 319 TERUMO BCT, INC.: PRODUCTS & SERVICES OFFERED 284
TABLE 320 TERUMO BCT, INC.: PRODUCT LAUNCHES & APPROVALS 285
TABLE 321 TERUMO BCT, INC.: DEALS 285
TABLE 322 TERUMO BCT, INC.: EXPANSIONS 286
13.1.2 FRESENIUS SE &CO. KGAA 287
TABLE 323 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW 287
FIGURE 53 FRESENIUS SE & CO KGAA: COMPANY SNAPSHOT (2022) 288
TABLE 324 FRESENIUS SE &CO. KGAA: PRODUCTS & SERVICES OFFERED 288
TABLE 325 FRESENIUS SE &CO. KGAA: PRODUCT LAUNCHES & APPROVALS 289
TABLE 326 FRESENIUS SE &CO. KGAA: DEALS 289
TABLE 327 FRESENIUS SE &CO. KGAA: EXPANSIONS 290
13.1.3 HAEMONETICS CORPORATION 291
TABLE 328 HAEMONETICS CORPORATION: BUSINESS OVERVIEW 291
FIGURE 54 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2023) 292
TABLE 329 HAEMONETICS CORPORATION: PRODUCTS & SERVICES OFFERED 292
TABLE 330 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS 293
TABLE 331 HAEMONETICS CORPORATION: DEALS 293
TABLE 332 HAEMONETICS CORPORATION: EXPANSIONS 294
13.1.4 BAXTER INTERNATIONAL INC. 295
TABLE 333 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW 295
FIGURE 55 BAXTER INTERNATIONAL INC: COMPANY SNAPSHOT (2023) 296
TABLE 334 BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES OFFERED 296
TABLE 335 BAXTER INTERNATIONAL INC: OTHERS 297
13.1.5 ASAHI KASEI MEDICAL CO., LTD. (SUBSIDIARY OF ASAHI KASEI CORPORATION) 298
TABLE 336 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW 298
FIGURE 56 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023) 299
TABLE 337 ASAHI KASEI CORPORATION: PRODUCTS & SERVICES OFFERED 299
13.1.6 B. BRAUN MELSUNGEN AG 301
TABLE 338 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW 301
FIGURE 57 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022) 302
TABLE 339 B. BRAUN MELSUNGEN AG: PRODUCTS & SERVICES OFFERED 302
TABLE 340 B. BRAUN MELSUNGEN AG: DEALS 303
TABLE 341 B. BRAUN MELSUNGEN AG: OTHERS 303
13.1.7 CERUS CORPORATION 304
TABLE 342 CERUS CORPORATION: BUSINESS OVERVIEW 304
FIGURE 58 CERUS CORPORATION: COMPANY SNAPSHOT (2023) 304
TABLE 343 CERUS CORPORATION: PRODUCTS & SERVICES OFFERED 305
TABLE 344 CERUS CORPORATION: PRODUCT LAUNCHES & APPROVALS 305
TABLE 345 CERUS CORPORATION: DEALS 305
TABLE 346 CERUS CORPORATION: OTHERS 306
13.1.8 KANEKA CORPORATION 307
TABLE 347 KANEKA CORPORATION: BUSINESS OVERVIEW 307
FIGURE 59 KANEKA CORPORATION: COMPANY SNAPSHOT (2023) 308
TABLE 348 KANEKA CORPORATION: PRODUCTS & SERVICES OFFERED 308
TABLE 349 KANEKA CORPORATION: DEALS 309
TABLE 350 KANEKA CORPORATION: OTHERS 309
13.1.9 SB-KAWASUMI LABORATORIES, INC. (SUBSIDIARY OF SUMITOMO BAKELITE CO., LTD.) 310
TABLE 351 SB-KAWASUMI LABORATORIES: BUSINESS OVERVIEW 310
FIGURE 60 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2023) 311
TABLE 352 SB-KAWASUMI LABORATORIES: PRODUCTS & SERVICES OFFERED 311
13.1.10 NIKKISO CO., LTD. 313
TABLE 353 NIKKISO CO., LTD.: BUSINESS OVERVIEW 313
FIGURE 61 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022) 314
TABLE 354 NIKKISO CO., LTD: PRODUCTS & SERVICES OFFERED 314
13.1.11 MACOPHARMA SA 315
TABLE 355 MACOPHARMA SA: BUSINESS OVERVIEW 315
TABLE 356 MACOPHARMA SA: PRODUCTS & SERVICES OFFERED 316
13.1.12 MILTENYI BIOTEC 317
TABLE 357 MILTENYI BIOTEC: BUSINESS OVERVIEW 317
TABLE 358 MILTENYI BIOTEC: PRODUCTS & SERVICES OFFERED 318
13.1.13 OTSUKA HOLDINGS CO., LTD. 319
TABLE 359 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW 319
FIGURE 62 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2022) 320
TABLE 360 OTSUKA HOLDINGS CO., LTD.: PRODUCTS & SERVICES OFFERED 320
13.1.14 MEDICA S.P.A. 321
TABLE 361 MEDICA S.P.A: BUSINESS OVERVIEW 321
TABLE 362 MEDICA S.P.A: PRODUCTS & SERVICES OFFERED 321
TABLE 363 MEDICA S.P.A: EXPANSIONS 322
13.1.15 MALLINCKRODT PLC 323
TABLE 364 MALLINCKRODT PLC: BUSINESS OVERVIEW 323
FIGURE 63 MALLINCKRODT PLC: COMPANY SNAPSHOT (2022) 324
TABLE 365 MALLINCKRODT PLC: PRODUCTS & SERVICES OFFERED 324
TABLE 366 MALLINCKRODT PLC: PRODUCT LAUNCHES & APPROVALS 324
13.1.16 BECTON, DICKINSON AND COMPANY 325
TABLE 367 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 325
FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 326
TABLE 368 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED 326
13.1.17 LMB TECHNOLOGIE GMBH 327
TABLE 369 LMB TECHNOLOGIE GMBH: BUSINESS OVERVIEW 327
TABLE 370 LMB TECHNOLOGIE GMBH: PRODUCTS & SERVICES OFFERED 327
13.1.18 BIOELETTRONICA S.R.L. 328
TABLE 371 BIOELETTRONICA S.R.L.: BUSINESS OVERVIEW 328
TABLE 372 BIOELETTRONICA S.R.L: PRODUCTS & SERVICES OFFERED 328
13.1.19 INFOMED SA 329
TABLE 373 INFOMED SA: BUSINESS OVERVIEW 329
TABLE 374 INFOMED SA: PRODUCTS & SERVICES OFFERED 329
13.1.20 CYTOSORBENTS CORPORATION 330
TABLE 375 CYTOSORBENTS CORPORATION: BUSINESS OVERVIEW 330
FIGURE 65 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2022) 331
TABLE 376 CYTOSORBENTS CORPORATION: PRODUCTS & SERVICES OFFERED 331
13.2 OTHER PLAYERS 332
13.2.1 MEDICAP CLINIC GMBH 332
13.2.2 HAIER BIOMEDICAL 332
13.2.3 BEIJING ZKSK TECHNOLOGY CO., LTD. 333
13.2.4 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD 333
13.2.5 PURIBLOOD MEDICAL 334
*Details on Business overview, Products/Solutions/Services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX 335
14.1 DISCUSSION GUIDE 335
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 340
14.3 CUSTOMIZATION OPTIONS 342
14.4 RELATED REPORTS 342
14.5 AUTHOR DETAILS 343